Cipla informs about updates

10 Feb 2026 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that a Pre-Approval Inspection (PAI) was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals, Inc. (‘InvaGen’), a wholly owned subsidiary of the Company, located in Hauppauge, Long Island, New York, USA, from 2nd February, 2026 to 9th February, 2026. On conclusion of the inspection, InvaGen has received 2 inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.

The above information is a part of company’s filings submitted to BSE. 

Cipla Share Price

1342.10 -0.35 (-0.03%)
10-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1707.55
Dr. Reddys Lab 1255.70
Cipla 1342.10
Zydus Lifesciences 887.20
Lupin 2204.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×